期刊
STROKE
卷 42, 期 7, 页码 1971-1975出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1161/STROKEAHA.110.595926
关键词
angioplasty and stenting; atherosclerosis; intracranial stenosis; outcome
资金
- Ministry of Health of The People's Republic of China [20080527]
- National Natural Science Foundation of China [30670731]
- Ministry of Science and Technology of The People's Republic of China [2006BA101A00]
Background and Purpose-There were limited data on the long-term outcome of patients with symptomatic intracranial atherosclerotic stenosis >= 70% after Wingspan stenting. Using our Wingspan cohort data and the data from the Warfarin and Aspirin for Symptomatic Intracranial Atherosclerotic Disease (WASID) as a historical control, we tested the hypothesis that stenting provided no benefit over antithrombotic therapy alone for these high-risk patients. Methods-Between January 2007 and February 2009, 100 consecutive patients with intracranial atherosclerotic stenosis >= 70% and symptoms within 90 days were enrolled into this prospective single-center Wingspan cohort study and followed up until the end of February 2010. Stenosis was measured per the WASID criteria. One-year risk of primary end point (any stroke or death within 30 days and ipsilateral ischemic stroke afterward) was compared with that of ipsilateral ischemic stroke in the WASID patients with >= 70% stenosis. Results-The stent placement success rate was 99%. All patients but 1 had clinical follow-up of >= 12 months. During a mean follow-up of 1.8 years, 9 patients developed primary end point events (5 within 30 days and 4 afterward). The 1-year risk of the outcome events was lower than that in similar WASID patients: 7.3% (95% CI, 2.0% to 12.5%) versus 18% (95% CI, 13% to 24%; P<0.05). Conclusions-The clinical outcome of Wingspan stenting for high-risk intracranial atherosclerotic stenosis patients in this high-volume center study compares favorably with that of antithrombotic therapy alone. A randomized trial comparing medical therapy alone with medical therapy plus Wingspan stenting, conducted at high-volume centers, is needed to confirm the stenting benefit. (Stroke. 2011; 42: 1971-1975.)
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据